Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Immunovant Q1 Earnings Call Highlights
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
Immunovant Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 109 | $2,239.39 | $4,264.08 | $2,024.69 | 90.41% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 41 | $1,442.83 | $1,603.92 | $161.09 | 11.16% |
 Farallon Capital Farallon Capital Management LLC | 5.8M | $202.52M | $225.56M | $23.04M | 11.38% |
| BG Bart Gancher Intech Investment Management LLC | 22,865 | $457,354.92 | $913,456.75 | $456,101.83 | 99.73% |
 John H. Burbank III Passport Capital LLC | 5.44M | $114.22M | $213.01M | $98.79M | 86.49% |
Immunovant Inc. (IMVT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunovant Inc. ever had a stock split?
Immunovant Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric Venker CEO | NASDAQ (NGS) Exchange | 45258J102 CUSIP |
| US Country | 315 Employees | - Last Dividend | - Last Split | 21 Jun 2019 IPO Date |
Overview
Immunovant, Inc. is a forward-looking biopharmaceutical company engaged in the development of innovative treatments for autoimmune diseases. Positioned at the clinical stage, Immunovant focuses on pioneering monoclonal antibody therapies, a cutting-edge segment of medicinal treatment that harnesses the body's immune system to combat disease. Headquartered in New York, New York, Immunovant operates under the umbrella of its parent company, Roivant Sciences Ltd., indicating a strong backing and extensive resources for its research endeavors and potential market influence.
Products and Services
- Batoclimab
- Myasthenia Gravis: A chronic autoimmune neuromuscular disease that leads to varying degrees of skeletal muscle weakness.
- Thyroid Eye Disease: An autoimmune condition that affects the orbit around the eye, characterized by inflammation, swelling, and eventually fibrosis, leading to discomfort and vision problems.
- Chronic Inflammatory Demyelinating Polyneuropathy: A neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
- Graves Diseases: An autoimmune disorder that results in the overproduction of thyroid hormones (hyperthyroidism).
- Warm Autoimmune Hemolytic Anemia: A condition where the immune system destroys red blood cells, leading to anemia.
A standout in Immunovant's portfolio, batoclimab represents a significant advancement in the monoclonal antibody domain, primarily targeting the neonatal fragment crystallizable receptor (FcRn). This novel, fully human antibody is currently under development for multiple autoimmune conditions, demonstrating the company’s commitment to addressing a range of challenging diseases. The conditions targeted by batoclimab include:
